Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours
Status:
Completed
Trial end date:
2020-06-10
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate the safety/tolerability, pharmacokinetic, and
pharmaco-dynamic effects of KA2507 and establish the maximum tolerated dose (MTD). Patients
with PD-L1 expressing solid tumors which have relapsed or are refractory to prior treatment
will be eligible to participate in this study.
Following completion of the multiple ascending dose study, the protocol may be amended to
include expansion cohorts in patients with melanoma and/or other solid tumors.